Drug intelligence / Profile preview

AZP-TSLP-BA1

Development stage: Preclinical
Lead developer: Azcuris
Modality: Small Molecules
Administration: Oral

Overview

AZP-TSLP-BA1 is a small-molecule antagonist of Thymic Stromal Lymphopoietin (TSLP) being developed by Azcuris Co., Ltd. It is part of Azcuris's TSLP program, which focuses on discovering and developing small-molecule protein-protein interaction (PPI) inhibitors targeting cytokines involved in immune diseases. The drug is designed to be an oral alternative to conventional injectable antibody drugs for allergic conditions such as asthma and atopic dermatitis. Its mechanism of action involves inhibiting the activity of TSLP, an upstream cytokine that plays a pivotal role in initiating and perpetuating inflammatory cascades in allergic diseases.

Targets

TSLPR (TSLP receptor)TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on AZP-TSLP-BA1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZP-TSLP-BA1.

Explore the full profile